Thermo Fisher Secures Phadia
Thermo Fisher Scientific Inc. of Waltham, Mass., has acquired Phadia of Uppsala, Sweden, a provider of blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases. Phadia now is part of Thermo Fisher’s Specialty Diagnostics business. The company is expected to contribute $0.07 to Thermo Fisher’s 2011 full-year adjusted earnings per share, an increase of $0.01 over the original estimate. In addition, it is expected to add $190 million to the US company’s 2011 revenue results, about a 12% growth in revenue over 2010.
LATEST NEWS
- Optogenetic Stimulation Enables Fatigue-Resistant Muscle Control
Jun 6, 2024
- Quandela Launches Pilot Line for Qubit Devices
Jun 6, 2024
- Lattice Semiconductor Adds Interim CEO
Jun 6, 2024
- On-Chip Microcomb Laser Provides Greater Control
Jun 5, 2024
- Flexible, Stretchable Device Addresses Tuning Limitations in Structural Color
Jun 5, 2024
- Fusion Startup Xcimer Raises $100M, Plans Laser Prototype
Jun 4, 2024
- ASML and imec Debut Joint Lithography Lab
Jun 4, 2024
- Photonic and Microsoft Detail Quantum Computing Milestone
Jun 4, 2024